In the current cycle, Century Therapeutics Inc (IPSC) Stock is showing signs of growth
JP Morgan lowered the price target for the Century Therapeutics Inc (NASDAQ:IPSC) stock from “an Overweight” to “a Neutral”. The rating was released on August 28, 2023, according to finviz. The research report from Guggenheim has initiated the stock to Buy, with a price target set at $15. The stock was initiated by Canaccord Genuity, […]
Century Therapeutics Inc (IPSC) Stock: Pessimism is a stepping stone to opportunity
JP Morgan lowered the price target for the Century Therapeutics Inc (NASDAQ:IPSC) stock from “an Overweight” to “a Neutral”. The rating was released on August 28, 2023, according to finviz. The research report from Guggenheim has initiated the stock to Buy, with a price target set at $15. The stock was initiated by Canaccord Genuity, […]
The future of Century Therapeutics Inc (IPSC) Stock is still in tatters?
JP Morgan lowered the price target for the Century Therapeutics Inc (NASDAQ:IPSC) stock from “an Overweight” to “a Neutral”. The rating was released on August 28, 2023, according to finviz. The research report from Guggenheim has initiated the stock to Buy, with a price target set at $15. The stock was initiated by Canaccord Genuity, […]
The high-quality value of Century Therapeutics Inc (IPSC) Stock is hidden beneath the surface
JP Morgan lowered the price target for the Century Therapeutics Inc (NASDAQ:IPSC) stock from “an Overweight” to “a Neutral”. The rating was released on August 28, 2023, according to finviz. The research report from Guggenheim has initiated the stock to Buy, with a price target set at $15. The stock was initiated by Canaccord Genuity, […]
